Purchase this article with an account.
I. Zundane, R. Adam, T. Rodallec, O. Laplace, Y. Salhi, B. Dufay-Dupar, F.-X. Broussaud, J.-P. Nordmann; Interest of Bevacizumab - Intravitreal Injection During Cataract - Surgery for Patients With Wet AMD. Invest. Ophthalmol. Vis. Sci. 2008;49(13):338.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
to evaluate benefit of intravitreal bevacizumab injection during cataract surgery.
14 patients with dense cataract with wet AMD were included in this study. All patients underwent full ophthalmological exam before the surgery, that included ETDRS, fluorescein angiography and/or indocyanine green angiography and OCT. At 1 month there was an ETDRS and angiography with OCT performed. At 6 months there was a control ETDRS and OCT assessed.
10 patients had occult new vessels and 4 patients mixed new vessels (predominantly classic new vessels). All had dense cataract. Mean visual acuity was 1/20 before operation and 3/10 at 6 months after surgery.12 patients had full disappearance of new vessels without recurrence. 2 patients had repeated intravitreal injection of bevacizumab 1 month after cataract surgery because of persistance of new vessels. There was no inflammatory postoperative complication. Intravitreal injections become current treatment in wet AMD.
combined cataract surgery with intravitreal bevacizumab injection can accelerate visual acuity recovery and diminish the risk of recurrence of new vessels if the wet AMD is associated with dense cataract often for an aged patient.
This PDF is available to Subscribers Only